RESI JPM 2025 Moves to San Francisco Marriott Marquis

Interview with Dennis Ford, Founder and CEO of Life Science Nation (LSN) By Caitlin Dolegowski, Marketing Manager, LSN

Dennis Ford
CaitiCaitlin Dolegowski

Life Science Nation (LSN) is elevating RESI JPM 2025 by moving to the San Francisco Marriott Marquis on January 14, 2025. This super-central venue, just minutes from Union Square, offers a spacious area with all activities on one floor. The new location allows for significantly expanded capacity, enhancing networking opportunities for attendees.

As the 50th RESI conference, this milestone event during JP Morgan Healthcare Week promises enhanced networking opportunities, great food, and the unique RESI format of equal representation between early-stage companies and investors/partners. RESI JPM continues its tradition of fostering crucial connections in the life science industry, building on its legacy of helping companies secure substantial funding and partnerships.

In an interview with Dennis Ford, CEO of Life Science Nation, he shared insights about this exciting location update for RESI JPM and its implications for the event’s future.

Caitlin Dolegowski (CD): What motivated the decision to move RESI JPM 2025 to the San Francisco Marriott Marquis?

Dennis Ford (DF): Forgive me, but let’s dial in the time machine and go back a decade to the third RESI event LSN had in 2014 at the iconic Baseball venue of Fenway Park, Kenmore Square, Boston. We had just launched Life Science Nation (LSN) and the Redefining Early Stage Investments (RESI) conference series and were two years in. My son Patrick worked at Fenway as a chef and introduced LSN to the catering folks who agreed to let RESI take over two of their big restaurant venues and stage an investor event complete with beer, hot dogs, and Boston clam chowder. At the RESI Fenway Park event, I met Ray Briscuso of AdvaMed, and we immediately hit it off. Ray is a well-known change agent in the life science arena and has created one of the world’s most dynamic MedTech partnering events. Ray loved what we were doing, connecting investors with startups, and he suggested bringing RESI to the JP Morgan event in San Francisco in January 2015.

With Ray’s encouragement, off I went to San Franciso, and I found one venue, the Marine Memorial Hotel, a few blocks away from Union Square. This is a small hotel, but it did have enough space to scatter a RESI event around the different floors with all the various nooks and crannies that this venerable older hotel offered us. RESI took over two floors connected by a stairway and launched the first RESI JPM, which we promptly sold out. At the inaugural RESI JPM event in that crowded hotel, the “collision factor” at RESI was born.

Our first RESI JPM was a packed house. The tight quarters had an exciting effect in that half the attendees were startups, and the other half were investors, and licensing partners kept literally bumping into each other as they traversed the hallways and staircases from scheduled meetings to panels and workshops. As the day went on, this collision prompted on-the-spot ad hoc meetings, which many reported were the best meetings of the day.

Typically, a partnering event has scheduled one-on-one meetings throughout the day. Still, at this event, the ad hoc meetings were equal to the number of scheduled meetings, which created a very different vibe because of the crowded facility. People were more open, friendly, and willing to chat and, if not a direct fit, make some referrals, and that aspect has carried over to every RESI event to this day.

Anyway, to make a long story short, we continued at the Marine Memorial for ten years, unable to find anything with more capacity, and stuck with our friends at the Marine Memorial, eventually taking over the entire hotel for the RESI event year after year. RESI JPM was limited in capacity to 1200 attendees, and most years, we were sold out because of a lack of capacity. RESI JPM developed a reputation as the place to find a capital investor and licensing partners; investors bump into other investors and find syndicate partners, and the relaxed community atmosphere came to define the community that supports our RESI events to this day. Fast forward a few weeks ago, and the Marriott Marquis had an opening this year with a 20,000 sq ft venue, and LSN felt we had to make a move and expand the RESI JPM partnering event. As it turns out, this RESI JPM will mark our 50th RESI event, and I still vividly recall an animated conversation with Ray overlooking the Fenway Park ball field telling me to get my ass to SF, CA, and find a hotel!

CD: How do you think the new Marriott Marquis location will enhance networking opportunities for attendees?

DF: JP Morgan Healthcare week has morphed into the most significant global partnering event in the world. The main reason many people travel to San Francisco in January is to participate in the numerous meetings and parallel events across the city’s downtown. These meetings start before the main JPM events and run throughout the week, offering diverse discussions and presentations from various organizations. LSN’s RESI JPM is one of the parallel events and is considered one of the go-to events of the week. The JPM gathering is still one of the premier global industry events and still fosters collaboration and innovation.

CD: Can you discuss the advantages of hosting the conference during JP Morgan Healthcare Week?

DF: Everyone who is anyone is at the JP Morgan week, and if you want to play in the life science arena, it is an opportunity to meet and network with the -players you need to be connected with.

CD: How do you anticipate the new venue will impact attendance numbers, particularly in terms of early-stage investors?

DF: LSN is about helping early-stage seed, 250k-2M, series A, 2M to 10M, and Series B 10-50M. RESI events cater to the buyers and sellers in this part of the life science landscape and is the place to be if you are an early-stage company seeking capital or licensing opportunities. At RESI JPM, attendees are equally divided between buyers and sellers. So we expect around 1500-2000 participants, equally divided between early-stage companies and investors and licensing partners seeking technology assets for their portfolios and product lines.

RESI conferences are unique because they are equally divided between early-stage life science companies across drugs, devices, diagnostics, and digital health and the investors and licensing partner entities.

CD: As RESI JPM 2025 marks the 50th RESI conference, how do you see this milestone event reflecting the growth and evolution of RESI over the years?

DF: RESI has helped over 400 companies raise over 5 billion dollars over the years. If any of these company’s technologies make it to a patient’s bedside and improve a patient’s outcome, then we will have done what we set out to do—make a difference.

RESI-SF-2025-Banner-1100px

Navigating the Treacherous Waters of Life Science Startups: Insights into Raising Capital 

By Dennis Ford, Founder and CEO of Life Science Nation

In the realm of the life sciences, startups emerge with promises of groundbreaking technologies and innovative solutions to complex medical challenges. However, statistics paint a stark reality: a staggering 95-99% of these ventures fail to secure the capital needed to survive and thrive. What factors contribute to such high failure rates, and what can these startups do to navigate the challenging landscape of fundraising effectively?

The Pitch Deck Predicament: Cookie-Cutter Presentations

It begins with the pitch. Most life science startups present their case through a standardized PowerPoint deck, ticking off boxes for “Problem,” “Solution,” and “Addressable Market.” Unfortunately, this approach often lacks the personal touch and compelling narrative needed to differentiate one firm from another. Investors, especially in early stages, seek more than scientific jargon—they crave stories that resonate, revealing the passion and expertise of the founding team.

The Problem: From Science to Story

Too often, the “Problem” is defined in clinical terms, devoid of a narrative that captures its human impact. What investors truly seek is a simple, easy-to-understand story that not only explains the problem scientifically but also connects emotionally with the audience. This personalized approach not only humanizes the issue but also highlights the unique insights and experiences of the team driving the solution forward. Of course, science matters, and it will be vetted as part of the due diligence process, but you need to grab the partner’s interest and deliver a story that is simple to understand, with some compelling hooks, to launch a potential relationship.

The Solution: Balancing Validation and Realism

Early-stage startups often face a dilemma with their “Solution.” Either they lack sufficient validated data points due to their developmental stage, or they present an overly optimistic view of an unproven technology. Finding the balance—demonstrating tangible progress while acknowledging the challenges ahead—is crucial. Investors appreciate transparency and a realistic assessment of risks alongside potential rewards.

Addressable Market: Knowing Your Audience

Presenting market size and dynamics might seem routine, but for life science startups, it’s crucial to tailor this information to the audience. Investors are often industry experts who know the market intricately. Therefore, startups must focus on demonstrating how their innovation fits within existing landscapes, addresses unmet needs effectively, and most importantly, what differentiates this technology from those currently available.

The Road to Investment: Preparation and Strategy

Beyond the pitch deck, startups must be adept at preparing for a global roadshow—a strategic tour aimed at attracting investors. This includes understanding the nuances of the “ask” (funding request) and validating it through rigorous preparation. Many founders overlook the fact that every fundraising round involves dilution of equity, emphasizing the importance of strategic planning and milestone-based financial projections.

Sales, Marketing, and Investor Relations

Sales and marketing fundamentals are often overlooked in the scientific rigor of life science startups. However, understanding how to position their technology, identify potential investors, and build meaningful relationships can significantly enhance their chances of success. This involves compiling lists of appropriate investors and licensing partners aligned with their stage of development and product offering.

Sponsorship Opportunities for RESI Boston 2024 and RESI JPM 2025: Connecting Early-Stage Life Science Innovators with Global Investors and Strategic Partners  

By Greg Mannix, VP, EMEA Business Development, LSN

Life Science Nation‘s (LSN) Redefining Early Stage Investments (RESI) Conference series is preparing for two major events: RESI Boston 2024 and RESI JPM 2025. These conferences offer exceptional opportunities for startups, investors, and strategic partners in the early-stage life science and healthcare sectors to connect and collaborate. RESI Boston 2024 is scheduled for September 25 at the Westin Copley Place, with virtual partnering on September 26-27. RESI JPM 2025 will occur on January 14, coinciding with the 43rd JPM Healthcare Conference in San Francisco, followed by virtual partnering on January 15-16. Now is the optimal time for companies to consider exhibitor and sponsorship packages for these events. These opportunities directly engage hundreds of RESI attendees, including early-stage startups, investors, and global strategic partners. Sponsorship benefits may include:

  • Prominent branding and visibility throughout the conference
  • Exhibition space to showcase products or services
  • Speaking opportunities in workshops
  • Find more target leads with LSN’s targeted support
  • Additional complimentary event registrations

RESI conferences are known for their cross-border and cross-domain approach, connecting startups with diverse global investors across drugs, devices, diagnostics, and digital health sectors. To explore RESI sponsorship or exhibitor opportunities that are the right fit for you, contact the LSN Business Development Team. With previous RESI conferences attracting over a thousand attendees, including more than 500 early-stage life science investors, these upcoming events are crucial for those looking to expand their presence in the life science and healthcare industries. Secure your sponsorship or exhibitor package now to ensure maximum visibility and engagement at RESI Boston 2024 and RESI JPM 2025.

RESI-Boston-2024-September-1100pxw

RESI-SF-2025-Banner-1100px

Hot Investor Profile: Venture Arm of Hospital System Seeks to Make Strategic Investments in Early-Stage Digital Health Companies

A venture arm of a hospital system started investing in early-stage companies through their venture team that was founded in 2022. The team focuses primarily in digital health companies seeking Pre-Seed to Series A investment rounds. The team’s mandate is solving clinical or operational challenges through strategic partnerships that align directly with the hospital system’s core values. The firm does not lead capital investments but will integrate strategic partners into the hospital system through pilot programs before eventually investing in equity. The firm’s equity investments are typically between USD $500k – $2M, but the fund can invest more. The fund is looking to invest in 4-6 companies yearly. 
 
The firm invests primarily within digital health companies that are ready to be integrated within the hospital system; the fund is opportunistic to indication and platform within their digital health investments. The firm may also make investments into diagnostics or medical device companies. For medical device investments, the fund prefers to invest in companies that are nearing clinical completion, or already on market. The fund does not invest in therapeutics. 
 
The fund does not have any strict company or management team requirements. Although an experienced management team is preferred, the fund is willing to invest in any company that is willing to provide tag-along rights. The fund invests within North America, Europe, Australia, and South America and is open to global opportunities that are capable of being integrated into the hospital system. The fund does not typically lead investments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: VC Firm Managing Multi-Billion AUM Invests in Life Science and Healthcare Technologies Across the Globe

A venture capital firm with multiple offices throughout US and outside of US invests in several areas of technology including biotech, medical devices and digital health. The firm participates in venture and growth investments as well as buyouts – allocations can range from $5-200m. The firm is open to global opportunities.  
 
Within the healthcare sector, the firm is highly interested in healthcare IT and also has some interest in medical devices and diagnostics. For devices and diagnostics, the firm has a strong preference for investing in products that have already achieved FDA clearance; only exceptional pre-clearance products will be considered and in those cases, the firm will only look at 510k products that are very close to approval; PMAs will not be considered. The firm is open to all indication areas, and has experience and expertise in diabetes, ENT, metabolic diseases, and the spine; the firm generally does not invest in highly invasive medical devices. The firm may also consider opportunities in laboratory tools and analytical drug discovery tools (but not drug discovery service models). In recent, the firm has expanded their investment areas into biotech and life sciences, and is open to investing across all modalities and indications in both pre-clinical and clinical stage assets. 
 
The firm invests in privately-held companies, and prefers to back experienced management teams with previous entrepreneurial successes. The firm prefers to invest in companies with over $2 million in revenue (over $3 million for healthcare IT companies), and with a customer base that includes large hospital networks or high-profile customers. Defensible IP is also a highly important factor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: Investor Group Invests in USA-Based Software-Enabled Devices, Digital Health, and Healthcare Services With Demonstrated Early Traction

An investor group based in the US is an investing ecosystem that includes Accredited Angel Investors, Healthcare Systems, and Corporate Venture Investors.  The firm focuses on healthcare IT, services and digital health from providers to consumers that changes the landscape of healthcare delivery. The firm prides itself in having built an ecosystem of qualified venture investors, corporate leaders and healthcare providers that open doors to strategic expertise and collaboration in the healthcare IT space. As an Angel-stage investor, the firm’s typical investment size can range, and can go from $100,000 to several million dollars. The firm also co-invests, and has made 24 series A/B investments so far, and is expecting 4-5 new investments and 4-5 repeat investments within the next year. The firm is open to companies throughout the USA, and has historically reviewed companies in Canada, though based on experience, prefer those that can manage the logistics of geographical distance. 
 
The firm focuses on healthcare IT, service, and digital health from providers to consumers that have a working prototype with an early pilot traction. The firm seeks products that serve hospitals at all parts of the continuum care spectrum, reaching to chronic care services that are past discharge and into long-term outpatient care. The firm also invests in devices that go to the consumer, as well as software-enabled technologies, such as connection technologies (i.e. Bluetooth, cell phone, etc.). The firm prefers no FDA regulated devices, and looks at pre-revenue technology with a foreseen horizon in terms of potential. The firm is also open to biotools and lab equipment, as they have historically invested in software and service models in the genomics area and technologies that organize clinical trials. 
 
While a management team must be in place, The firm has an experienced team of members with the ability to mentor and fill management teams with expertise. The firm typically takes a board seat after leading an investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: Canada-Based VC Invests in Pre-Seed and Seed Stage Companies Across the Globe in All Areas of Life Sciences & Healthcare

A venture capital firm headquartered in Canada likes to be an early-believer and invest in early-stage companies in niche areas that are often overlooked. Interested areas include, but are not limited to, healthcare, food tech, education, clean tech, software and more. The firm only invests in Pre-Seed and Seed stage companies and will typically allocate between $25k-500k USD. The firm has co-led and led rounds, but mainly acts as a co-investor and is open to global companies. 
 
The firm is sector-agnostic and in terms of life science, will invest in devices, health tech, drug discovery, and diagnostics. The firm invests in companies that are pre-phase I and/or in-development. The firm is also indication agnostic. 
 
The firm strongly emphasizes and looks for a dedicated and full-time team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.